Loading...
Although direct-acting antiviral agents (DAAs) used in treating hepatitis C virus (HCV) infection are highly effective, a small percentage of patients still fail therapy.
In two industry-funded, phase III studies, researchers evaluated the efficacy and safety of a combination of sofosbuvir (SOF), an NS5B inhibitor; velpatasvir (VEL), an NS5A inhibitor; and voxilaprevir (VOX), a protease inhibitor, in HCV-infected patients who previously failed a DAA-containing therapy.
In one study, 300 patients with HCV genotype 1 who previously failed an NS5A-containing regimen were randomized to receive a single pill of SOF/VEL/VOX or placebo daily for 12 weeks. Another 114 patients with other HCV genotypes were enrolled into the SOF/VEL/VOX group. Rates o…